NAPRELAN (naproxen)

SELF ADMINISTRATION - Oral

Indications for Prior Authorization:
  • Indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout.  It is also indicated in the relief of mild to moderate pain and the treatment of primary dysmenorrhea.
Patients must meet the following criteria for the indication(s) above:
  • Used for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, acute gout, mild to moderate pain, or primary dysmenorrhea, AND
  • Chart note documentation is provided and confirms: patient has tried and failed two preferred generic prescription strength oral NSAIDs (nonsteroidal antiinflammatory drugs), one of the two must be generic Naproxen regular-release tablets OR there is a medically appropriate reason why generic alternatives cannot be tried
Dosing:
  • Rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis:
    • Starting dose: two Naprelan® 375 mg tablets (750 mg) once daily, one Naprelan® 750 mg once daily, or two Naprelan® 500 mg tablets (1000 mg) once daily.
    • Dose may be increased to two Naprelan® 750 mg tablets (1500 mg) or three Naprelan® 500 mg (1500 mg) once daily for limited periods when a higher level of antiinflammatory/analgesic activity is required.
    • A lower dose should be considered in patients with renal or hepatic impairment or in elderly patients.
  • Management of pain, primary dysmenorrhea, and acute tendinitis and bursitis:
    • Starting dose: two Naprelan® 500 mg tablets (1000 mg) once daily
    • If needed, two Naprelan® 750 mg tablets (1500 mg) or three Naprelan® 500 mg tablets (1500 mg) may be used for a limited period.  Thereafter, the total daily dose should not exceed two Naprelan® 500 mg tablets (1000 mg).
  • Acute gout:
    • First day: two to three Naprelan® 500 mg tablets (1000 - 1500 mg) once daily, followed by two Naprelan® 500 mg tablets (1000 mg) once daily, until the attack has subsided

Last review date: July 17, 2018